Cellectis SA (CLLS) has released an update.
Cellectis, a biotech firm specializing in gene-editing therapies, is set to announce its first quarter financial results for 2024 on May 28, after US market close. The announcement will be accompanied by an investor call on May 29, detailing the quarterly results and business updates. The company, known for its CAR-T immunotherapies and gene editing in hemopoietic stem cells, is a pioneer in off-the-shelf cancer treatments.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.
